Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former FBI Cyber Chief Urges More Proactive Approach to Cybersecurity

Executive Summary

Medtech companies need to up its game in fighting cybersecurity threats, says former chief of FBI’s cyber operations section. If not dealt with effectively, these threats can affect the function of pacemakers or compromise the intellectual property of manufacturers developing new drugs. While the risks of cyberattacks are growing, industry response has been lackadaisical at best, according to Jerry Bessette.

You may also be interested in...

Cyber Insurance Offerings Growing In Response To New Threats

Insurers are reformulating their policies for device firms and others to meet the new threat of cyber attacks in the health-care arena, according to experts from the law firm Covington & Burling.

Security Firm Confirms 'Petya' Has Affected Medical Devices

A cybersecurity expert with TrapX says the firm has at least one hospital client whose medical devices have been adversely affected by the so-called "Petya" ransomware worm. He is also concerned the recent "WannaCry" and Petya attacks are just tests for a far greater threat yet to come.

Hack Attack: Biopharma Cyber Chiefs Fight Back

News that Merck & Co was affected by the recent global ransomware attack hits home the increasing importance of cybersecurity. In Vivo recently hosted a roundtable of information security officers on how to prepare for the growing threat of cyber attack.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts